UroGen Pharma (URGN) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Company overview and technology

• Developed RTGel, a reverse thermal gel that enables sustained drug delivery in the urinary tract, addressing a key challenge in urothelial cancer treatment.

• Commercialized two products: JELMYTO for upper tract urothelial carcinoma and ZUSDURI for low-grade intermediate-risk bladder cancer.

• ZUSDURI recently approved for a larger patient population, expanding the addressable market to about 60,000 patients annually in the U.S.

Market opportunity and launch dynamics

• The target market for ZUSDURI is about 10 times larger than JELMYTO, with significant unmet need due to high recurrence rates and reliance on repetitive surgery.

• Early launch saw $1.8M in Q3 revenue, with October alone reaching $4.5M, indicating rapid uptake.

• Operational complexities and reimbursement processes initially slowed adoption, but a permanent J-code from January streamlined access.

• About one-third of patients are considered high unmet need, often elderly or with multiple recurrences.

Clinical data and physician feedback

• ZUSDURI achieved an 80% complete response rate, with 80% of those maintaining response at 12 months.

• Patient-reported outcomes show 90% prefer ZUSDURI over surgery, and physicians are enthusiastic about the alternative to TURBT.

• Most patients receive all six doses, and early real-world feedback aligns with clinical trial results.